Clinical trial
Zylet vs TobraDex in Blepharokeratoconjunctivitis
NCT00447577 · Bausch & Lomb Incorporated, Industry · Completed
Key facts
| NCT number | NCT00447577 |
|---|---|
| Title | Zylet vs TobraDex in Blepharokeratoconjunctivitis |
| Official title | A Clinical Safety and Efficacy Evaluation of Zylet (Loteprednol Etabonate and Tobramycin Ophthalmic Suspension) vs. Tobradex (Tobramycin and Dexamethasone Ophthalmic Suspension) in the Treatment of Blepharokeratoconjunctivitis |
| Lead sponsor | Bausch & Lomb Incorporated, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Blepharokeratoconjunctivitis |
| Intervention type | Drug |
| Interventions | Loteprednol etabonate and tobramycin ophthalmic suspension, Tobramycin and dexamethasone ophthalmic suspension |
| Enrollment | 276 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Mar 14, 2007 |
| Last update posted | Dec 9, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: